GPR119, a novel G protein-coupled receptor target for the ...
We express our gratitude to our many colleagues at (OSI) Prosidion and OSI Pharmaceuticals Inc. who have contributed to the GPR119 project. ...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2268073/...
|
BNY76078_WO25_OSI_Cvr4_1:OSI 01_Mech_Cover 1.2
17 Jun 2009 ... our GPR119 agonist; and PSN602 – our next generation sibutramine competitor compound). We have .... At OSI, we see the goal of delivering shareholder value
... President, OSI Prosidion. Robert L. Simon ...
http://www.osip.com/pdf/Shareholder%20Letter%202008.pdf...
|
GPR119 agonists for the treatment of type 2 diabetes.
With the passage of the first GPR119 agonist clinical candidates into Phase I trials (Arena/Ortho McNeil APD597; Metabolex MBX-2982; Prosidion/OSI PSN821) ...
http://www.ncbi.nlm.nih.gov/pubmed/19780700...
|
Diabetes & Obesity
PSN821 has been selected as a product candidate from the GPR119 agonist project for the ... (OSI) Prosidion is the diabetes and obesity R&D group within OSI ...
http://www.osip.com/products_diabetes_obesity...
|
GPR119, a novel G protein-coupled receptor target for the ...
(OSI) Prosidion, Windrush Court, Oxford, UK. hoverton@prosidion.com. GPR119 is a G protein-coupled receptor expressed predominantly in the pancreas ...
http://www.ncbi.nlm.nih.gov/pubmed/18037923...
|
annual report 2007
sound business sense for OSI. We are convinced that disciplined investments in differentiated ... in the clinic has given Prosidion a running start. For
example, .... GPR119 agonist. PSN821 acts by causing GLP-1 release and ...
http://www.osip.com/pdf/OSIAR2007%20FINAL%20(Single%20Page)....
|
Deorphanization of a G protein-coupled receptor for ...
(OSI)Prosidion, Windrush Court, Watlington Road, Oxford OX4 6LT, ... paper presents evidence that OEA is an endogenous ligand of the orphan receptor GPR119
, ...
http://www.ncbi.nlm.nih.gov/pubmed/16517404...
|
Summary of OSI PHARMACEUTICALS INC - Yahoo! Finance
10 Nov 2008 ... Prosidion contributes an important second source of revenues to us from ... a first-in-human clinical study for our GPR119 agonist, PSN821, ...
http://biz.yahoo.com/e/081110/osip10-q.html...
|
Summary of OSI PHARMACEUTICALS INC - Yahoo! Finance
7 Aug 2009 ... Prosidion Limited, our U.K. subsidiary which conducts our research and ... or GPR119, agonist with potential anti-diabetic and appetite ...
http://biz.yahoo.com/e/090807/osip10-q.html...
|
